Highly Expressed miR-375 is not an Intracellular Oncogene in Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma.

Hippo signaling Merkel cell carcinoma antagomiRs focal adhesion miR-375

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
25 Feb 2020
Historique:
received: 06 01 2020
revised: 12 02 2020
accepted: 24 02 2020
entrez: 29 2 2020
pubmed: 29 2 2020
medline: 29 2 2020
Statut: epublish

Résumé

miR-375 is a highly abundant miRNA in Merkel cell carcinoma (MCC). In other cancers, it acts as either a tumor suppressor or oncogene. While free-circulating miR-375 serves as a surrogate marker for tumor burden in patients with advanced MCC, its function within MCC cells has not been established. Nearly complete miR-375 knockdown in MCC cell lines was achieved using antagomiRs via nucleofection. The cell viability, growth characteristics, and morphology were not altered by this knockdown. miR-375 target genes and related signaling pathways were determined using Encyclopedia of RNA Interactomes (ENCORI) revealing Hippo signaling and epithelial to mesenchymal transition (EMT)-related genes likely to be regulated. Therefore, their expression was analyzed by multiplexed qRT-PCR after miR-375 knockdown, demonstrating only a limited change in expression. In summary, highly effective miR-375 knockdown in classical MCC cell lines did not significantly change the cell viability, morphology, or oncogenic signaling pathways. These observations render miR-375 an unlikely intracellular oncogene in MCC cells, thus suggesting that likely functions of miR-375 for the intercellular communication of MCC should be addressed.

Identifiants

pubmed: 32106526
pii: cancers12030529
doi: 10.3390/cancers12030529
pmc: PMC7139599
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : European Commission
ID : 277775

Déclaration de conflit d'intérêts

J.C. Becker is receiving speaker’s bureau honoraria from Amgen, Pfizer, MerckSerono, and Sanofi, and is a paid consultant/advisory board member for eTheRNA, MerckSerono, Pfizer, 4SC, REcordati, InProTher, and Sanofi. His group receives research grants from IQVIA, Merck Serono, and Alcedis. None of the activities are related to the submitted work. None of the other authors indicated any potential conflicts of interest.

Références

J Invest Dermatol. 2020 Jan;140(1):56-65.e3
pubmed: 31283928
Int J Cancer. 2020 Mar 15;146(6):1652-1666
pubmed: 31180579
Onco Targets Ther. 2017 Jul 10;10:3353-3362
pubmed: 28744139
Sci Transl Med. 2012 May 9;4(133):133ra56
pubmed: 22572880
Cancer Genet. 2016 Jan-Feb;209(1-2):30-5
pubmed: 26725423
Cancer Res. 2017 Dec 15;77(24):6812-6817
pubmed: 29208606
J Invest Dermatol. 2015 Apr;135(4):1138-1146
pubmed: 25521454
Cell Res. 2010 Jul;20(7):784-93
pubmed: 20548334
Eur Urol. 2015 Jan;67(1):33-41
pubmed: 25129854
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Mol Cancer Res. 2011 Jun;9(6):791-800
pubmed: 21593139
J Clin Invest. 2013 Jun;123(6):2694-702
pubmed: 23728175
Cancers (Basel). 2018 Nov 14;10(11):
pubmed: 30441870
Oncogene. 2004 Apr 8;23(15):2732-42
pubmed: 14755241
Mol Med Rep. 2012 May;5(5):1299-304
pubmed: 22377847
Nature. 2012 Jul 26;487(7408):491-5
pubmed: 22810586
Nature. 2005 Dec 1;438(7068):685-9
pubmed: 16258535
Genome Res. 2017 Oct;27(10):1665-1673
pubmed: 28904014
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5813-8
pubmed: 19289822
Nat Methods. 2012 Mar 04;9(4):403-9
pubmed: 22388288
J Ovarian Res. 2019 Jan 22;12(1):6
pubmed: 30670062
Science. 2001 Oct 26;294(5543):853-8
pubmed: 11679670
Nature. 2004 Nov 11;432(7014):226-30
pubmed: 15538371
J Cell Sci. 2013 Jan 1;126(Pt 1):21-9
pubmed: 23516327
Cancer Res. 2015 Dec 15;75(24):5228-34
pubmed: 26627015
Nat Rev Dis Primers. 2017 Oct 26;3:17077
pubmed: 29072302
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7
pubmed: 24297251
Nucleic Acids Res. 2007;35(9):2885-92
pubmed: 17439965
J Cell Mol Med. 2012 Nov;16(11):2655-66
pubmed: 22469014
Clin Cancer Res. 2019 Oct 1;25(19):5961-5971
pubmed: 31399473
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
Oncol Res. 2012;20(5-6):197-203
pubmed: 23581226
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Cancer Res. 2010 Mar 15;70(6):2339-49
pubmed: 20215506
Exp Mol Pathol. 2013 Aug;95(1):62-7
pubmed: 23685355
J Invest Dermatol. 2014 Feb;134(2):507-517
pubmed: 23962809
Mol Cancer. 2018 Dec 4;17(1):170
pubmed: 30514309
Oncogene. 2012 Jul 12;31(28):3357-69
pubmed: 22056881
Clin Cancer Res. 2018 Dec 1;24(23):5873-5882
pubmed: 30061360
Am J Pathol. 2016 Apr;186(4):1025-35
pubmed: 26877261
J Invest Dermatol. 2017 Jan;137(1):197-206
pubmed: 27592799
Nat Methods. 2009 Jan;6(1):63-6
pubmed: 19043411
Oncotarget. 2016 May 31;7(22):32956-68
pubmed: 27121059
Int J Cancer. 2019 Aug 15;145(4):1020-1032
pubmed: 30873613
Elife. 2015 Aug 12;4:
pubmed: 26267216

Auteurs

Kaiji Fan (K)

Department of Translational Skin Cancer Research, University Hospital Essen, 45141 Essen, Germany.
German Cancer Consortium (DKTK), 45141 Essen, Germany.
German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Department of Dermatology, Medical University of Graz, 8010 Graz, Austria.

Armin Zebisch (A)

Division of Hematology, Medical University of Graz, 8010 Graz, Austria.
Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Division of Pharmacology, Medical University of Graz, 8010 Graz, Austria.

Kai Horny (K)

Department of Translational Skin Cancer Research, University Hospital Essen, 45141 Essen, Germany.
German Cancer Consortium (DKTK), 45141 Essen, Germany.
German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

David Schrama (D)

Department of Dermatology, University Hospital Würzburg, 97080 Würzburg, Germany.

Jürgen C Becker (JC)

Department of Translational Skin Cancer Research, University Hospital Essen, 45141 Essen, Germany.
German Cancer Consortium (DKTK), 45141 Essen, Germany.
German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Department of Dermatology, University Hospital Essen, 45147 Essen, Germany.

Classifications MeSH